EYP-1901 for Wet Age-Related Macular Degeneration

LUGANO is a Phase 3 non-inferiority trial of EYP-1901 vs aflibercept q8W on BCVA averaged at Weeks 52/56. Phase 2 DAVIO 2 met its noninferiority primary endpoint with stable BCVA and strong burden reduction, supporting reasonable probability of success. However, extending dosing interval to 6 months (vs q8W aflibercept) raises risk of BCVA drift near trough; sustained-release TKI Phase 3s carry meaningful failure risk. Modest edge above coin flip.

Phase 3 status and objective BCVA endpoint support credible readout quality, but wet AMD active-comparator vision outcomes at 52/56 weeks are demanding. Fields provide no prior efficacy, margin, sample size, or masking details, leaving material uncertainty despite active-not-recruiting execution.

Phase 3 active-not-recruiting trial with standard BCVA change endpoint at 52/56 weeks vs aflibercept; no Phase 2 data, powering details, or effect-size guidance in fields; imminent readout (66 days) but typical Ph3 execution and disclosure risks apply.

EYP-1901 (sustained-release vorolanib) already demonstrated statistical non-inferiority to aflibercept in the 161-patient Phase 2 DAVIO 2 trial. The Phase 3 LUGANO trial utilizes a similar design (2.7mg dosed every 6 months) and allows supplemental aflibercept rescue therapy. Permitting standard-of-care rescue strongly protects the BCVA non-inferiority primary endpoint, making clinical success highly probable. A recent DSMC review recommended continuing without changes, further de-risking the trial.

Phase 3 non-inferiority trial of EYP-1901 vs aflibercept for wet AMD. Phase 2 showed comparable BCVA change with durable effect. Primary endpoint averaging Weeks 52 and 56 reduces variability. Typical Phase 3 success for anti-VEGF sustained delivery is moderate; prior TKI implant data supportive but not definitive. Estimate ~60% chance of positive result.

Phase 2 DAVIO trial showed EYP-1901 maintained BCVA comparable to aflibercept with reduced injection burden. Phase 3 non-inferiority design on BCVA is achievable given prior data and established Durasert platform. Risks include longer 52/56-week durability vs 6-month Phase 2, potential rescue therapy confounding, and typical Phase 3 failure rate. Overall slightly favor YES resolution.

EYP-1901's Durasert technology enables sustained aflibercept delivery, addressing adherence issues in wet AMD. Phase 2 data showed non-inferiority to standard care with extended dosing intervals. Phase 3 design mirrors successful prior trials. Strong mechanistic rationale and positive prior data support a likely positive BCVA outcome, though Phase 3 execution risk remains.

Phase‑3 wet AMD trial with BCVA change at 1 year. No disclosed prior efficacy data for EYP‑1901 versus aflibercept, making outcome uncertain. Endpoint is standard and measurable, but novel agent risk and lack of recruiting suggest modest chance of a positive result, roughly 45%.

Phase 3 wet AMD trial with BCVA endpoint at weeks 52/56. EYP-1901 is a sustained-release vorolanib implant vs aflibercept standard-of-care. Prior Phase 2 DAVIO data showed non-inferiority but not superiority, with some safety signals. Active-not-recruiting status with 66 days to completion suggests database lock imminent, limiting upside from new info. Wet AMD trials have high placebo/drug effect and demanding regulators. Sustained-release formulations historically struggle to beat q2m aflibercept on vision endpoints. Disclosure risk elevated with completion near.

EYP-1901 anti-VEGF sustained-release therapy in Phase 3 for wet AMD. Phase 3 in this established mechanism carries ~60-65% success. BCVA endpoint is gold standard, enrollment complete reduces execution risk. Market price of 45 cents undervalues ~62% intrinsic odds.